Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)

SHE:300267 Revenue

Hunan Er-Kang Pharmaceutical had revenue of 320.17M CNY in the quarter ending June 30, 2026, a decrease of -2.49%. This brings the company's total for the last twelve months to 1.05B, down -12.39% year-over-year. In the year 2025, Hunan Er-Kang Pharmaceutical had annual revenue of 1.17B with 2.29% growth. That makes Hunan Er-Kang Pharmaceutical the 19,223rd largest company in the world by revenue and 3,509th in China.

• Revenue (ttm): 1.05B
• Revenue Growth: -12.39%
• P/S Ratio: 5.69
• Revenue / Employee: 827.25K
• Employees: 1,271
• Market Cap: 5.98B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Industry 919.26M 78.9%
• New Energy Industry 213.28M 18.3%
• Others 33.22M 2.8%

By Geography

Chart

• Central China 275.40M 23.6%
• Southern China 261.94M 22.5%
• East China 223.34M 19.2%
• Overseas 167.18M 14.3%
• North China 87.97M 7.5%
• Southwest Region 78.54M 6.7%
• North-East China 42.38M 3.6%
• North-West China 29.01M 2.5%

Fiscal year ended Dec 31, 2025 See the full SHE:300267 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.17B	26.15M	2.29%
Dec 31, 2024	1.14B	-643.51M	-36.09%
Dec 31, 2023	1.78B	-87.42M	-4.67%
Jan 1, 2023	1.87B	-364.76M	-16.32%
Jan 1, 2022	2.24B	-146.97M	-6.17%

Data Source: S&P Global Market Intelligence Last updated: Aug 26, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error